LNTH

Rating neutralTentativeAI MemoPost-earnings T+3

Lantheus

As of 2026-08-08/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

report lacks a dated company-specific catalyst beyond generic cadence for its sector profile

Action

neutral

Confidence

high

Horizon

—

Key catalyst

Curium merger cash consideration creates a near-term price anchor • 2026-11-06

Base target: $103 / p=60% prob

Biggest risk

Standalone momentum remains modest: Q2 revenue grew only 2.7%, PYLARIFY declined 4.1%, and adjusted EPS declined 1.3%. Guidance withdrawal, the lack of an earnings call, merger-completion risk, and uncertainty around CVR milestones limit forward visibility. No post-print analyst target or estimate revisions are available.

Invalidation

Break below $88 or thesis failure.

What would change my mind?

The Curium transaction provides a $102.50 cash anchor, potential CVR upside to $114.50, and a strategic combination spanning diagnostics and therapeutics. Lantheus also reported $92.2 million of operating cash flow and $593.3 million of cash at June 30, 2026. [#SEC-8K-2026-08-06]

Research note

Recommendation

neutral

Confidence

high

As of

2026-08-08

Base target

$103

p=60%

Bull target

$115

p=20%

Bear target

$88

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 results were operationally mixed and guidance was suspended
PYLARIFY TruVu launch is planned for Q4 2026
Conditional CVR upside depends on product milestones

BearKey bullets

Curium transaction completion could be delayed or fail, leaving the stock exposed to standalone repricing.
Lantheus suspended previously issued full-year 2026 guidance and will not hold a Q2 earnings call, reducing forward disclosure.
No post-earnings analyst revisions, target changes, or estimate updates are available in the packet.

WatchKey bullets

Curium merger cash consideration creates a near-term price anchor

Summary

High-level snapshot

Recommendation

neutral

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $103 (p=60%)

Target spread vs base: +12% / -14%

Scenario probabilities

Bull Target: $115 (p=20%)Base Target: $103 (p=60%)Bear Target: $88 (p=20%)

Commentary

News tone is mixed and dominated by the pending Curium transaction: the cash consideration is supportive, while Q2 operating results were modest and guidance was suspended. The August 7 anchor price of $100.95 sits just below the $102.50 cash component, indicating a narrow deal spread. Post-print analyst reaction and social coverage are unavailable; high headline buzz is event-driven rather than evidence of improving fundamentals.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 results were operationally mixed and guidance was suspended
PYLARIFY TruVu launch is planned for Q4 2026
Conditional CVR upside depends on product milestones

Scenarios

Bull Target (Scenario probability)

$115 / p=20% prob

Base Target (Scenario probability)

$103 / p=60% prob

Bear Target (Scenario probability)

$88 / p=20% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-06
Curium merger cash consideration creates a near-term price anchor
Lantheus agreed to be acquired for $102.50 per share in cash plus non-transferable CVRs worth up to $12.00 per share, subject to commercial milestones through 2030. The board unanimously approved the transaction, announced August 3, 2026; closing timing and completion conditions remain unavailable in the packet. [#SEC-8K-2026-08-06]
Prob 80.00% • Move 1.50% • Priced-in 95.00%

Short-term Catalysts

Next few weeks

Q2 results were operationally mixed and guidance was suspended
2026-08-06
Lantheus reported Q2 results on August 6, 2026: revenue rose 2.7% to $388.2 million, adjusted EPS declined 1.3% to $1.55, and PYLARIFY sales fell 4.1% to $240.4 million. The company suspended full-year 2026 guidance and will not host a quarterly earnings call because of the pending transaction. [#SEC-8K-2026-08-06]
Prob 75% • Move -2% • Priced-in 85%

Long-term Catalysts

Months to a year

PYLARIFY TruVu launch is planned for Q4 2026
2027-08-08
Lantheus reported FDA approval for PYLARIFY TruVu and said a phased geographic launch was planned to begin in the fourth quarter of 2026. The launch remains a potential operating catalyst, although the pending transaction and suspended guidance reduce visibility into its standalone equity impact. [#SEC-8K-2026-05-07]
Prob 50% • Move 3% • Priced-in 40%
Conditional CVR upside depends on product milestones
2027-08-08
The transaction includes potential additional cash payments of up to $12.00 per share through 2030, contingent on specified commercial milestones. This provides upside beyond the cash consideration but remains conditional and unquantified by management in the available earnings release. [#SEC-8K-2026-08-06]
Prob 35% • Move 12% • Priced-in 20%

Risks

Curium transaction completion could be delayed or fail, leaving the stock exposed to standalone repricing.
Lantheus suspended previously issued full-year 2026 guidance and will not hold a Q2 earnings call, reducing forward disclosure.
No post-earnings analyst revisions, target changes, or estimate updates are available in the packet.
PYLARIFY sales declined 4.1% year over year in Q2, while adjusted EPS declined 1.3%.
The $12.00 per-share CVR is conditional on commercial milestones and may not be fully realized.
The planned Q4 2026 PYLARIFY TruVu launch carries execution and commercialization risk, and its standalone value is obscured by the pending transaction.

Peers

Symbol	Summary
TLX	Closest listed operating comparator: Telix is a commercial-stage radiopharmaceutical company focused on diagnostic and therapeutic theranostics, including PSMA-related products. Comparability is strongest in oncology radiopharma, though product mix differs.
NVS	Large diversified pharmaceutical comparator with radiopharmaceutical oncology exposure. Relevant for radioligand competition, but scale and diversification make it a loose valuation comp.
CAH	Radiopharmacy and distribution-channel comparator rather than a direct product peer; relevant to U.S. availability and supply-chain access for radiopharmaceuticals.
BSX	Broad medtech reference for healthcare-device sector context, but not a direct radiopharmaceutical operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

TLX

Closest listed operating comparator: Telix is a commercial-stage radiopharmaceutical company focused on diagnostic and therapeutic theranostics, including PSMA-related products. Comparability is strongest in oncology radiopharma, though product mix differs.

NVS

Large diversified pharmaceutical comparator with radiopharmaceutical oncology exposure. Relevant for radioligand competition, but scale and diversification make it a loose valuation comp.

CAH

Radiopharmacy and distribution-channel comparator rather than a direct product peer; relevant to U.S. availability and supply-chain access for radiopharmaceuticals.

BSX

Broad medtech reference for healthcare-device sector context, but not a direct radiopharmaceutical operating peer.